Author

C. E. Tognon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Cheltsov· 1 shared A. Nilsen· 1 shared B. Druker· 1 shared C. Boniface· 1 shared D. Bottomly· 1 shared D. Rozanov· 1 shared E. Traer· 1 shared G. B. Mills· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cheltsov

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

S. K. Joshi, S. Sharzehi, J. Pittsenbarger, D. Bottomly, C. E. Tognon, S. McWeeney, B. Druker, E. Traer

This study identifies a novel FLT3 mutation, N701K, that confers resistance to gilteritinib by blocking its binding, and suggests switching to type 2 FLT3 inhibitors may be effective.

bioRxiv · Jan 27, 2021Cancer Biology

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity

D. Rozanov, A. Cheltsov, A. Nilsen, C. Boniface, J. Korkola, J. Gray, J. Tyner, C. E. Tognon, G. B. Mills, P. Spellman

The paper identifies key factors distinguishing non-toxic and toxic compounds targeting mitochondria in cancer therapy using SAR studies and a mathematical model.

bioRxiv · Oct 1, 2018Cancer Biology